SELLAS Life Sciences Group priced a public common-stock offering at $13 a share, aiming to raise capital through the sale of newly issued shares. The company expects net proceeds of about $161.8 million if the underwriters exercise their option in full.
The financing increases SELLAS’s cash and share count. It is not a change in control or management.
Key details
- SELLAS agreed to sell 11,538,462 shares, which would generate about $150 million before underwriting discounts, commissions and other offering expenses.
- The underwriters have 30 days to buy up to 1,730,769 additional shares at the same price. If they take the full allotment, the total offering would be about 13.27 million shares and gross proceeds about $172.5 million.
- The company’s estimated net proceeds of approximately $161.8 million include the full exercise of that option; the announcement does not establish that the option had already been exercised.
- The offering was expected to close on or about November 20, 2026, subject to customary closing conditions.
Plain-English implications
Because the offering consists of newly issued common stock, existing shareholders’ ownership will be diluted. The final scale of that dilution depends in part on whether the underwriters exercise their option.
